• Adagene published a medical research presentation outlining clinical progress for ADG126 (muzastotug), a masked anti-CTLA-4 antibody with FDA Fast Track status.
• Interim results highlighted efficacy with low discontinuations in late-line MSS colorectal cancer patients without liver metastases.
• Sanofi-backed plan included up to USD 25 million equity investment support for a randomized Phase 2 ADG126-pembrolizumab study in that subgroup.
• Cash balance was about USD 128 million as of June 30, 2026; runway projected into late 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.